deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT00527878

Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome

A Double-Blind, Randomized, Placebo-Controlled Cross-Over Study Assessing the Role of Pathogen-Specific IgE and Histamine Release in the Hyper-IgE Syndrome and the Effect of Ranitidine on Laboratory and Clinical Manifestations

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Hyper-IgE Recurrent Infection Syndrome Immune Deficiency JOB's Syndrome
Interventions Placebo Ranitidine
Updated 7 times since 2017 Last updated: Feb 1, 2013 Started: Sep 30, 2007 Primary completion: Jun 30, 2011 Completion: Jun 30, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Failure to enroll adequate patient numbers due to small number of eligible patients

Other terminated trials from National Institute of Allergy and Infectious Diseases (NIAID)

See all terminations from National Institute of Allergy and Infectious Diseases (NIAID)

A PHASE2 clinical study on Hyper-IgE Recurrent Infection Syndrome and Immune Deficiency, this trial is terminated or withdrawn. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 7 data snapshots since 2007. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshotTerminated~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotTerminated~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

  5. Jan 2021 — Dec 2022 [monthly]

    Terminated PHASE2

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  2. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations